- Investigator
- Torge Rempe
- Status
- Accepting Candidates
Torge Rempe, MD, PhD : Research
Neurologist
Rated
4.7
out of 5 stars
- Additional languages:
- Spanish,
- German
Research at a glance
Top areas of exploration
- Autoantibodies , 4 publications
- Disease Progression , 3 publications
- Myelin-Oligodendrocyte Glycoprotein , 3 publications
- Neuromyelitis Optica , 3 publications
Research activity
Active clinical trials
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 40 Years - 70 Years
- Sexes
- All
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
My publications
Filter publications
33 publications
2026
Factors associated with delays in multiple sclerosis disease-modifying therapy initiation
Multiple Sclerosis Journal – Experimental, Translational and Clinical
Publisher's site2026
Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis
Multiple Sclerosis Journal – Experimental, Translational and Clinical
Publisher's site2026
Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis
Multiple Sclerosis Journal – Experimental, Translational and Clinical
Publisher's site2025
A Multi-Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions.
Annals of clinical and translational neurology
PubMed • Publisher's site2025
The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants.
Contemporary clinical trials
PubMed • Publisher's site